Dosage ; 5 mg slow I.V or by I.V inf. shortly before chemotherapy
followed by 5 mg orally every morning at least an hour before food for 5 days.
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Navoban | Novartis Pharma | Surgipharm Ltd | 5mg | 1 | Injection | per ml | KES 2,190.00 |
| Navoban | Novartis Pharma | Surgipharm Ltd | 5mg | 5 | Injection | per vial | KES 9,461.00 |
| Tropisetron More info | |
|---|---|
| Mode Of Action | A specific serotonin (5HT3) antagonist (Emetogenics like cytotoxic drugs and radiation damage gastrointestinal mucosa. This leads to the release of serotonin from the enterochromaffin cells of the gastrointestinal tract. 5-HT3 receptors are stimulated causing transmission of sensory signals to the vomiting center via vagal afferent fibers to induce vomiting. Granisetron binds to the 5-HT3 receptors hence blocking vomiting mediated by serotonin release). |
| Drug Indication | Reserved for use in patients on cytotoxics who cannot tolerate or whose nausea and vomiting is not controlled by less expensive drugs. |
| Precautions | Pregnancy and lactation; severe hepatic impairment; uncontrolled hypertension; |
| Contra-Indications | Hypersensitivity to tropisetron and related compounds. |
| Side Effects | Constipation; diarrhoea; fever; dizziness; drowsiness; sedation; shivers; urinary retention; hypotension; headache; flushing; transient rise in liver enzymes; rarely hypersensitivity reactions; syncope; bradycardia. |
| Dosage | 5 mg slow I.V or by I.V inf. shortly before chemotherapy followed by 5 mg orally every morning at least an hour before food for 5 days. |
| Pregnancy Category | Category B1 |
| Pregnancy Category Description | Drugs which have been taken by only a small number of pregnant women and women of child-bearing age with no any established rise in the frequency of malformations or other direct or indirect detrimental effects on the foetus having been noted. Studies in animals have not shown evidence of an increased occurrence of foetal damage. |
| Drug Category | DRUGS ACTING ON ALIMENTARY SYSTEM |
| Drug Sub-Category | HT antagonists |